KRAS and prostate carcinoma: DU145 cells, which have a KRAS gene rearrangement [24], did not have high levels of any oncogenic ETS protein, or pAKT, but did have pERK, consistent with the small fraction of prostate cancers with RAS/ERK pathway mutations (Table 1).